Thomasius F, Palacios S, Alam A, et al. - Researchers identified a lower incidence of fractures among patients prescribed risedronate gastro-resistant (GR) vs other bisphosphonates, which may be due to the fact that absorption of the GR formulation occurred even when taken with food.

• Fracture rates and outcomes between osteoporosis women treated with risedronate GR (GR cohort) vs other oral bisphosphonates (other cohort) were determined via analyzing claim data in the USA.

• Each cohort comprised 2,726 patients (median age: 60.0 years).

• Lower incidence of fractures in the GR cohort for any fracture sites and spine fractures.

• Medication discontinuation rate at 2 years was 80.5% and 74.4% for the GR vs other cohort.

• The GR cohort had delayed time to first fracture, attaining statistical significance after 36 months.

• Fewer hospitalizations were recorded in the GR cohort, translating into lower hospitalization costs per patient per year.